|
1
|
Jiang JP, Shen XF, Du JF and Guan WX: A
retrospective study of 34 patients with unicentric and multicentric
Castleman's disease: Experience from a single institution. Oncol
Lett. 15:2407–2412. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Casper C: The aetiology and management of
Castleman disease at 50 years: Translating pathophysiology to
patient care. Br J Haematol. 129:3–17. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Krause JR, Robinson SD and Vance EA:
Multicentric Castleman's disease and HIV. Proc Bayl Univ Med Cent.
27:28–30. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Suda T, Katano H, Delsol G, Kakiuchi C,
Nakamura T, Shiota M, Sata T, Higashihara M and Mori S: HHV-8
infection status of AIDS-unrelated and AIDS-associated multicentric
Castleman's disease. Pathol Int. 51:671–679. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fajgenbaum DC, van Rhee F and Nabel CS:
HHV-8-negative, idiopathic multicentric Castleman disease: Novel
insights into biology, pathogenesis, and therapy. Blood.
123:2924–2933. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Talat N, Belgaumkar AP and Schulte KM:
Surgery in Castleman's disease: A systematic review of 404
published cases. Ann Surg. 255:677–684. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Keller AR, Hochholzer L and Castleman B:
Hyaline-vascular and plasma-cell types of giant lymph node
hyperplasia of the mediastinum and other locations. Cancer.
29:670–683. 1972.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Castleman B, Iverson L and Menendez VP:
Localized mediastinal lymphnode hyperplasia resembling thymoma.
Cancer. 9:822–830. 1956.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Talat N and Schulte KM: Castleman's
disease: Systematic analysis of 416 patients from the literature.
Oncologist. 16:1316–1324. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yu L, Tu M, Cortes J, Xu-Monette ZY,
Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA,
et al: Clinical and pathological characteristics of HIV- and
HHV-8-negative Castleman disease. Blood. 129:1658–1668.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma
K, Zhu XL, Liu XY and Sun KL: A retrospective study of unicentric
and multicentric Castleman's disease: A report of 52 patients. Med
Oncol Northwood Lond Engl. 27:1171–1178. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu W, Cai Q, Yu T, Strati P, Hagemeister
FB, Zhai Q, Zhang M, Li L, Fang X, Li J, et al: Clinical
characteristics and outcomes of Castleman disease: A multicenter
Consortium study of 428 patients with 15-year follow-up. Am J
Cancer Res. 12:4227–4240. 2022.PubMed/NCBI
|
|
14
|
Dispenzieri A and Fajgenbaum DC: Overview
of Castleman disease. Blood. 135:1353–1364. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
van Rhee F, Oksenhendler E, Srkalovic G,
Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S,
Streetly M, et al: International evidence-based consensus
diagnostic and treatment guidelines for unicentric Castleman
disease. Blood Adv. 4:6039–6050. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dispenzieri A, Armitage JO, Loe MJ, Geyer
SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K,
Dogan A and Habermann TM: The clinical spectrum of Castleman's
disease. Am J Hematol. 87:997–1002. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Neuhof D and Debus J: Outcome and late
complications of radiotherapy in patients with unicentric Castleman
disease. Acta Oncol Stockh Swed. 45:1126–1131. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bower M, Powles T, Williams S, Davis TN,
Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, et al:
Brief communication: Rituximab in HIV-associated multicentric
Castleman disease. Ann Intern Med. 147:836–839. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pria AD, Pinato D, Roe J, Naresh K, Nelson
M and Bower M: Relapse of HHV-8-positive multicentric Castleman
disease following rituximab-based therapy in HIV-positive patients.
Blood. 129:2143–2147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Van Rhee F, Voorhees P, Dispenzieri A,
Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson
SK, et al: International, evidence-based consensus treatment
guidelines for idiopathic multicentric Castleman disease. Blood.
132:2115–2124. 2018.PubMed/NCBI View Article : Google Scholar
|
